Navigation Links
Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10
Date:10/11/2011

LONDON, October 12, 2011 /PRNewswire/ --

- Two pivotal trials initiated for treatment of iron deficiency anaemia associated with ulcerative colitis and Crohn's disease -

Shield Therapeutics (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need, today announced that the first patients have been treated in the two Phase 3 clinical studies of ST10 for the treatment of iron deficiency anaemia (IDA) in subjects with inflammatory bowel disease (IBD).

"Following our successful fundraising in June, we are delighted to have now treated the first patients in the AEGIS Phase 3 programme and we remain on course to have top line results from these studies in late 2012.  Effective treatment of IDA represents a very attractive commercial opportunity and the start of recruitment is an important milestone for Shield Therapeutics as we continue the rapid development of ST10 to address this significant unmet need for the many patients with IDA." said Carl Sterritt, Chief Executive Officer and Co-Founder of Shield Therapeutics.

ST10 is an oral ferric iron-based pharmaceutical that can be administered to patients with improved tolerability compared to currently marketed oral iron treatments and also does not carry the risk of hypersensitivity reactions as is the case with currently marketed intravenous iron therapies.  Whilst prescribers often try oral ferrous products as first line therapy, many subjects prove intolerant and suffer from continuously occurring side effects, exacerbation of inflammatory lesions and failure to correct iron deficiency.  This results in the need for expensive, complicated and invasive intravenous iron therapy.  When treated with ST10, the total dose exposure of unabsorbed iron within the gastrointestinal tr
'/>"/>

SOURCE Shield Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cord Blood America Enters Agreement With Regence, Serving BlueCross and BlueShield Programs in the Northwest U.S. and Mountain Regions
2. TCT 2009 to Feature vProtect(TM) Luminal Shield, a Novel Treatment Designed for Soft Coronary Lesions from Prescient Medical
3. vProtect(TM) Luminal Shield Stabilizes Life-Threatening Plaque
4. SyntheMed Announces FDA Clearance of SinusShield(TM)
5. NanoVibronix Receives FDA Clearance for its PainShield(TM) MD Device
6. United Therapeutics Announces Proposed Private Offering of $210 Million of Convertible Senior Notes and Authorization of Stock Repurchase Program
7. United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
8. Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology
9. Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
10. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
11. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)...  MiMedx Group, Inc. (NASDAQ: MDXG ), the ... patent-protected processes to develop and market advanced products and ... Medicine, Ophthalmic and Dental sectors of healthcare, announced that ... been awarded the Lifetime Achievement Award in the EY ... The Entrepreneur Of The Year Program, now in ...
(Date:6/29/2015)... June 29, 2015   Veracyte, Inc . (Nasdaq: ... field of molecular cytology, today announced that it has ... Top Workplaces list for the second year in a ... solely on an annual survey of Bay Area-company employees. ... the degree to which Veracyte values our employees and ...
(Date:6/26/2015)... , June 26, 2015   Aratana ... a pet therapeutics company focused on the ... products for companion animals, today announced positive ... of capromorelin (AT-002), the company,s innovative therapeutic ... a small molecule that mimics ghrelin, the ...
(Date:6/26/2015)... NEW YORK and MUMBAI, India ... (TCS), (BSE: 532540, NSE: TCS) a leading global IT ... has been designated as a Leader in Worldwide Life ... IDC, in the " IDC MarketScape: Worldwide Life Science ... 2015) report. The report evaluated eight ...
Breaking Biology Technology:EY Entrepreneur Of The Year Program Recognizes Pete Petit, The Chairman & CEO of MiMedx 2Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 2Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 3Aratana Therapeutics Announces Positive Pivotal Results for AT-002 2Aratana Therapeutics Announces Positive Pivotal Results for AT-002 3Aratana Therapeutics Announces Positive Pivotal Results for AT-002 4Aratana Therapeutics Announces Positive Pivotal Results for AT-002 5TCS Recognized as a Leader in Life Sciences R&D Risk-Based Monitoring by IDC MarketScape 2TCS Recognized as a Leader in Life Sciences R&D Risk-Based Monitoring by IDC MarketScape 3TCS Recognized as a Leader in Life Sciences R&D Risk-Based Monitoring by IDC MarketScape 4
... , , , ... 20 The Molecular Genetics Core Facility (MGCF) at ... genetics researchers to conduct the highly economic targeted enrichment of ... will be receiving the Geniom RT Analyzer® from febit to ...
... , Washington , Jan. ... Alnylam announced today that the organizations are partnering to engage the ... and Alnylam Intellectual Property (IP) Pool.  The IP Pool was formed ... development of new medicines for the treatment of 16 neglected tropical ...
... ... (IPS), a leading, full-service engineering, construction, commissioning and qualification company dedicated to assisting ... Wareheim as Bioprocess Subject Matter Expert. , ... Lafayette Hill, PA (Vocus) January 20, 2010 ...
Cached Biology Technology:Molecular Genetics Core Facility at Children's Hospital Boston Selects HybSelect from febit for Targeted Resequencing 2Molecular Genetics Core Facility at Children's Hospital Boston Selects HybSelect from febit for Targeted Resequencing 3BIO Ventures for Global Health Chosen to Administer the GSK and Alnylam Intellectual Property Pool 2BIO Ventures for Global Health Chosen to Administer the GSK and Alnylam Intellectual Property Pool 3BIO Ventures for Global Health Chosen to Administer the GSK and Alnylam Intellectual Property Pool 4IPS Appoints Dave Wareheim as Bioprocess Subject Matter Expert 2IPS Appoints Dave Wareheim as Bioprocess Subject Matter Expert 3
(Date:6/23/2015)... Minn. , June 23, 2015   ... company that supports the entire spectrum of clinical ... iMedNet ™ , the company,s intuitive, ... been awarded a Silver 2015 Stevie® Award by ... Health Products & Services Website category.  The American ...
(Date:6/18/2015)... , June 18, 2015 This report analyzes ... by the following Product Segments, which includes Immunoassay Analyzers ... Immunoassay Systems, Radio Immunoassay Systems, and Nephelometric Immunoassay Systems. ... Canada , Japan ... , Latin America , and ...
(Date:6/17/2015)... June 17, 2015  Synaptics Inc. (NASDAQ: ... today announced that Xiaomi, one of the world,s ... ClearPad ® family of capacitive touchscreen ... circuits (DDICs) for its latest smartphones, the Xiaomi ... for full in-cell display solutions and DDICs in ...
Breaking Biology News(10 mins):MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3
... be the key to creating cyborg interfaces? Circuitry that links ... such as a robotic limb or artificial eye might one ... Writing in the International Journal of Medical Engineering ... "memristor" can be made using human blood. Memristors were a ...
... (Baltimore, MD) Today, the Interactive Autism Network (IAN), ... first major survey to study the experience of wandering ... disorders (ASD). The tendency of individuals with ASD to ... injury or even death, yet information on this critical ...
... State University has revealed a potential new way for plants ... and molecular biology professor, cites that this defense mechanism is ... plants and herbivores. Howe, in the current issue of ... offers insights to understanding the chemical weaponry of this war, ...
Cached Biology News:Blood simple circuitry for cyborgs 2Why do children with autism wander and bolt from safe places? 2The way to (kill) a bug's heart is through its stomach 2
Mouse monoclonal antibody raised against a partial recombinant ALPK3. NCBI Entrez Gene ID = ALPK3...
Mouse monoclonal antibody raised against a partial recombinant MYO7A. NCBI Entrez Gene ID = MYO7A...
... Cell Lines ,High Quality, Functionally-Validated, Ion Channel ... known for having a critical role in ... a key function in pain, CNS and ... have been investigated in therapeutic areas, such ...
Mouse monoclonal antibody raised against a partial recombinant ENTPD5. NCBI Entrez Gene ID = ENTPD5...
Biology Products: